# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $73 price target.
On Wednesday, Cathie Wood-led Ark Invest made significant trades in Roku Inc (NASDAQ:ROKU) and Coinbase Global Inc (NASDAQ:COIN...
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine wi...
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 ...
Cantor Fitzgerald analyst Rick Bienkowski reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and maintains $65...
Truist Securities analyst Joon Lee maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $120 price target.
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.